Caris Life Sciences, Inc.
CAI
We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.05B
▲ +97.0% YoY
Net Income (TTM)
$96M
▲ +75.8% YoY
Op. Margin
13.35%
▲ +67.9pp YoY
ROIC
13.26%
▲ +100.7pp YoY
Cash Flow & Balance Sheet
FCF (FY)
$67M
▲ +126.4% YoY
Op. Cash Flow (TTM)
$84M
▲ +133.9% YoY
Net Debt
-$370M
Net Cash Position
Cash & Equiv.
$799M
Continue Research
Peers
Services-Medical Laboratories · Pick stocks to compare with CAI
Held by ETFs
CAI is in 54 US ETFs. The largest of them, with CAI's weight in each:
Caris Life Sciences (CAI) in four numbers
Questions about Caris Life Sciences
Is Caris Life Sciences (CAI) overvalued?
At $25.23, Caris Life Sciences' price is 443% above the $4.65 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 3.04 times earnings and 108.16 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Caris Life Sciences' fair value?
Intrinsiqq's calculator puts Caris Life Sciences' fair value at $4.65 a share. It grows earnings per share 5% a year for 5 years, applies an exit P/E of 17.5, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $3.48. Every input can be changed on the Intrinsic Value tab.
Is Caris Life Sciences a high-quality business?
Caris Life Sciences scores 71 out of 100 on Intrinsiqq's quality score, which makes it a solid business on these measures. The score blends 7 checks computed from SEC filings. Its best check is revenue growth at 50.7%, and its weakest is share count change at 744.6%. The Quality tab shows every check against its target.
Does Caris Life Sciences (CAI) pay a dividend?
No. Caris Life Sciences (CAI) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 0.4% buyback yield. The Dividends tab shows its cash returns.
Source: 10-Q filed 2 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 6 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in CAI's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CAI
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.